This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, J. Articles by Richmond, A. Search for Related Content PubMed PubMed Citation Articles by Yang, J. Articles by Richmond, A.

Constitutive IB Kinase Activity Correlates with Nuclear Factor-B Activation in Human Melanoma Cells¹

Veterans Affairs Medical Center [A. R.] and Department of Cancer Biology [J. Y., A. R.], Vanderbilt University School of Medicine, Nashville, Tennessee 37232

Constitutive IKK activity associated with increased IB phosphorylation and degradation contribute to the high level of endogenous nuclear factor-B (NF-B) activation in Hs294T melanoma cells as compared with RPE cells (R. L. Shattuck-Brandt and A. Richmond, Cancer Res., 57: 3032–3039, 1997; M. N. Devalaraja et al., Cancer Res., 59: 1372–1377, 1999). To determine whether this endogenous NF-B activation was characteristic of melanoma, we examined the level of constitutive activation of NF-B in a number of melanoma cell lines. We demonstrate here that eight melanoma cell lines exhibit increased IB kinase (IKK) activity, enhanced phosphorylation of IB and p65, and enhanced nuclear localization of p65/p50 in comparison to normal human epidermal melanocytes. The chemokines, CXC ligand 1 (CXCL1) and CXCL8, but not CXCL5, are highly expressed in most of the melanoma cell lines, suggesting that the constitutive production of chemokines is highly correlated to endogenous NF-B activity. Our failure to observe a direct relationship between the fold activation of IKK, CXCL1, or CXCL8 mRNA levels and secretion of these chemokines into the culture medium suggest that regulation of chemokine expression also occurs at the posttranscription level of mRNA stability and/or translational control. Moreover, recombinant CXCL1 can directly induce IKK activity in normal human epidermal melanocytes in a concentration-dependent manner after up-modulation of CXCL1 protein expression, whereas inhibition of IKKß activity results in down-modulation of CXCL1 protein expression. Finally, CXCL1 antibody blocks IKK activity and inhibits the proliferation of melanoma cells to further support the concept that the constitutive activation of NF-B and autocrine effects of CXCL1 play an important role in the pathogenesis of melanoma.

This article has been cited by other articles:

				J. Yang, S. Zaja-Milatovic, Y.-M. Thu, F. Lee, R. Smykla, and A. Richmond Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy Mol. Cancer Ther., March 1, 2009; 8(3): 636 - 647. [Abstract] [Full Text] [PDF]

				Y. Xia, R. C. Padre, T. H. De Mendoza, V. Bottero, V. B. Tergaonkar, and I. M. Verma Phosphorylation of p53 by I{kappa}B kinase 2 promotes its degradation by {beta}-TrCP PNAS, February 24, 2009; 106(8): 2629 - 2634. [Abstract] [Full Text] [PDF]

				P. Dhawan, Y. Su, Y. M. Thu, Y. Yu, P. Baugher, D. L. Ellis, T. Sobolik-Delmaire, M. Kelley, T. C. Cheung, C. F. Ware, et al. The Lymphotoxin-{beta} Receptor Is an Upstream Activator of NF-{kappa}B-mediated Transcription in Melanoma Cells J. Biol. Chem., May 30, 2008; 283(22): 15399 - 15408. [Abstract] [Full Text] [PDF]

				G. Sethi, B. Sung, and B. B. Aggarwal Nuclear Factor-{kappa}B Activation: From Bench to Bedside Experimental Biology and Medicine, January 1, 2008; 233(1): 21 - 31. [Abstract] [Full Text] [PDF]

				S. Braunstein, S. C. Formenti, and R. J. Schneider Acquisition of Stable Inducible Up-Regulation of Nuclear Factor-{kappa}B by Tumor Necrosis Factor Exposure Confers Increased Radiation Resistance without Increased Transformation in Breast Cancer Cells Mol. Cancer Res., January 1, 2008; 6(1): 78 - 88. [Abstract] [Full Text] [PDF]

				I. Bieche, C. Chavey, C. Andrieu, M. Busson, S. Vacher, L. Le Corre, J.-M. Guinebretiere, S. Burlinchon, R. Lidereau, and G. Lazennec CXC chemokines located in the 4q21 region are up-regulated in breast cancer Endocr. Relat. Cancer, December 1, 2007; 14(4): 1039 - 1052. [Abstract] [Full Text] [PDF]

				J. Yang, W.-H. Pan, G. A. Clawson, and A. Richmond Systemic Targeting Inhibitor of {kappa}B Kinase Inhibits Melanoma Tumor Growth Cancer Res., April 1, 2007; 67(7): 3127 - 3134. [Abstract] [Full Text] [PDF]

				V. Fernandez-Majada, C. Aguilera, A. Villanueva, F. Vilardell, A. Robert-Moreno, A. Aytes, F. X. Real, G. Capella, M. W. Mayo, L. Espinosa, et al. Nuclear IKK activity leads to dysregulated Notch-dependent gene expression in colorectal cancer PNAS, January 2, 2007; 104(1): 276 - 281. [Abstract] [Full Text] [PDF]

				R. Loewe, T. Valero, S. Kremling, B. Pratscher, R. Kunstfeld, H. Pehamberger, and P. Petzelbauer Dimethylfumarate Impairs Melanoma Growth and Metastasis Cancer Res., December 15, 2006; 66(24): 11888 - 11896. [Abstract] [Full Text] [PDF]

				J. A. Sosman and I. Puzanov Molecular targets in melanoma from angiogenesis to apoptosis. Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s. [Abstract] [Full Text] [PDF]

				J. Yang, K. I. Amiri, J. R. Burke, J. A. Schmid, and A. Richmond BMS-345541 Targets Inhibitor of {kappa}B Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor {kappa}B and Mitochondria Pathways Clin. Cancer Res., February 1, 2006; 12(3): 950 - 960. [Abstract] [Full Text] [PDF]

				G. Matsumoto, J.-i. Namekawa, M. Muta, T. Nakamura, H. Bando, K. Tohyama, M. Toi, and K. Umezawa Targeting of Nuclear Factor {kappa}B Pathways by Dehydroxymethylepoxyquinomicin, a Novel Inhibitor of Breast Carcinomas: Antitumor and Antiangiogenic Potential In vivo Clin. Cancer Res., February 1, 2005; 11(3): 1287 - 1293. [Abstract] [Full Text] [PDF]

				H. Cheng, C. Cenciarelli, G. Nelkin, R. Tsan, D. Fan, C. Cheng-Mayer, and I. J. Fidler Molecular Mechanism of hTid-1, the Human Homolog of Drosophila Tumor Suppressor l(2)Tid, in the Regulation of NF-{kappa}B Activity and Suppression of Tumor Growth Mol. Cell. Biol., January 1, 2005; 25(1): 44 - 59. [Abstract] [Full Text] [PDF]

				S. S. Brar, C. Grigg, K. S. Wilson, W. D. Holder Jr., D. Dreau, C. Austin, M. Foster, A. J. Ghio, A. R. Whorton, G. W. Stowell, et al. Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease Mol. Cancer Ther., September 1, 2004; 3(9): 1049 - 1060. [Abstract] [Full Text] [PDF]

				A. Munshi, J. F. Kurland, T. Nishikawa, P. J. Chiao, M. Andreeff, and R. E. Meyn Inhibition of constitutively activated nuclear factor-{kappa}B radiosensitizes human melanoma cells Mol. Cancer Ther., August 1, 2004; 3(8): 985 - 992. [Abstract] [Full Text] [PDF]

				K. I. Amiri, L. W. Horton, B. J. LaFleur, J. A. Sosman, and A. Richmond Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition: Implication for Bortezomib (VELCADE, PS-341) as a Therapeutic Agent for Malignant Melanoma Cancer Res., July 15, 2004; 64(14): 4912 - 4918. [Abstract] [Full Text] [PDF]

				O. P. Veiby and M. A. Read Chemoresistance: Impact of Nuclear Factor (NF)-{kappa}B Inhibition by Small Interfering RNA: Commentary re J. Guo et al., Enhanced Chemosensitivity to Irinotecan by RNA Interference-Mediated Down-Regulation of the NF-{kappa}B p65 Subunit. Clin Cancer Res 2004;10:3333-3341 Clin. Cancer Res., May 15, 2004; 10(10): 3262 - 3264. [Full Text] [PDF]

				R. D. Sue, J. A. Belperio, M. D. Burdick, L. A. Murray, Y. Y. Xue, M. C. Dy, J. J. Kwon, M. P. Keane, and R. M. Strieter CXCR2 Is Critical to Hyperoxia-Induced Lung Injury J. Immunol., March 15, 2004; 172(6): 3860 - 3868. [Abstract] [Full Text] [PDF]

				Y. Takada and B. B. Aggarwal Betulinic Acid Suppresses Carcinogen-Induced NF-{kappa}B Activation Through Inhibition of I{kappa}B{alpha} Kinase and p65 Phosphorylation: Abrogation of Cyclooxygenase-2 and Matrix Metalloprotease-9 J. Immunol., September 15, 2003; 171(6): 3278 - 3286. [Abstract] [Full Text] [PDF]

				Y. Bayon, M. A. Ortiz, F. J. Lopez-Hernandez, F. Gao, M. Karin, M. Pfahl, and F. J. Piedrafita Inhibition of I{kappa}B Kinase by a New Class of Retinoid-Related Anticancer Agents That Induce Apoptosis Mol. Cell. Biol., February 1, 2003; 23(3): 1061 - 1074. [Abstract] [Full Text]

				P. Dhawan and A. Richmond Role of CXCL1 in tumorigenesis of melanoma J. Leukoc. Biol., July 1, 2002; 72(1): 9 - 18. [Abstract] [Full Text] [PDF]

				A. Ariga, J.-i. Namekawa, N. Matsumoto, J.-i. Inoue, and K. Umezawa Inhibition of Tumor Necrosis Factor-alpha -induced Nuclear Translocation and Activation of NF-kappa B by Dehydroxymethylepoxyquinomicin J. Biol. Chem., June 28, 2002; 277(27): 24625 - 24630. [Abstract] [Full Text] [PDF]

				A. Birbach, P. Gold, B. R. Binder, E. Hofer, R. de Martin, and J. A. Schmid Signaling Molecules of the NF-kappa B Pathway Shuttle Constitutively between Cytoplasm and Nucleus J. Biol. Chem., March 22, 2002; 277(13): 10842 - 10851. [Abstract] [Full Text] [PDF]

				P. Dhawan and A. Richmond A Novel NF-kappa B-inducing Kinase-MAPK Signaling Pathway Up-regulates NF-kappa B Activity in Melanoma Cells J. Biol. Chem., March 1, 2002; 277(10): 7920 - 7928. [Abstract] [Full Text] [PDF]

				A. Arlt, J. Vorndamm, S. Muerkoster, H. Yu, W. E. Schmidt, U. R. Folsch, and H. Schafer Autocrine Production of Interleukin 1{beta} Confers Constitutive Nuclear Factor {kappa}B Activity and Chemoresistance in Pancreatic Carcinoma Cell Lines Cancer Res., February 1, 2002; 62(3): 910 - 916. [Abstract] [Full Text] [PDF]

				J. Yang, G.-H. Fan, B. E. Wadzinski, H. Sakurai, and A. Richmond Protein Phosphatase 2A Interacts with and Directly Dephosphorylates RelA J. Biol. Chem., December 14, 2001; 276(51): 47828 - 47833. [Abstract] [Full Text] [PDF]

				S. S. Brar, T. P. Kennedy, A. B. Sturrock, T. P. Huecksteadt, M. T. Quinn, A. R. Whorton, and J. R. Hoidal An NAD(P)H oxidase regulates growth and transcription in melanoma cells Am J Physiol Cell Physiol, June 1, 2002; 282(6): C1212 - C1224. [Abstract] [Full Text] [PDF]